[Microdose clinical trial--impact of PET molecular imaging].
Microdose (MD) clinical trial and exploratory IND study including sub-therapeutic dose and therapeutic dose which are higher than microdoses are expected to bring about innovations in drug development. The outlines of guidances for microdose clinical trial and ICH-M3 (R2) issued by the MHLW in June, 2008, and February, 2010, are first explained, respectively, and some examples of their application to clinical developments of therapeutic drugs in the infection and cancer fields are introduced. Especially, thanks to the progress of molecular imaging research, a new field of drug development is explored by using imaging biomarkers for efficacy or safety evaluation which visualize biomarkers by PET imaging agents. Finally, the roadmap for drug development in infection and cancer fields utilizing PET molecular imaging is discussed.
Yano
Tsuneo
T
RIKEN, Center for Molecular Imaging Science, Hyogo, Japan.
Watanabe
Yasuyoshi
Y
D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000032:analysis*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D049268:Positron-Emission Tomography / Q000379:methods*
D015415:Biomarkers; D003287:Contrast Media